Georgia Research Alliance

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Lucid Scientific develops real-time cellular activity monitors for drug discovery and research. It serves academic institutions and pharmaceutical companies, offering innovative tools like RESIPHER for non-invasive, continuous measurement of oxygen consumption in cell cultures.

Lucid Scientific develops real-time cellular activity monitors for drug discovery and research. It serves academic institutions and pharmaceutical companies, offering innovative tools like RESIPHER for non-invasive, continuous measurement of oxygen consumption in cell cultures.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

Lucid Scientific develops real-time cellular activity monitors for drug discovery and research. It serves academic institutions and pharmaceutical companies, offering innovative tools like RESIPHER for non-invasive, continuous measurement of oxygen consumption in cell cultures.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Urjanet, Inc. is a company that specializes in providing a cloud-based platform for automated access to utility data. Founded in 2009 and headquartered in Atlanta, Georgia, with an additional location in Chennai, India, Urjanet connects directly to utility providers to acquire and normalize utility bills and interval data. Its offerings include automated access to utility bill data across various utilities, granular measurements of energy consumption, and advanced metering infrastructure data without requiring additional hardware or software. The platform also features capabilities for weather data analysis and alerts for billing and consumption anomalies. Urjanet's solutions are designed to improve business intelligence, energy management, accounting, and procurement processes for organizations, enabling them to enhance financial performance, energy efficiency, and sustainability.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

MoQuality Inc. is a technology company founded in 2014 and headquartered in Atlanta, Georgia, that specializes in artificial intelligence-driven mobile testing solutions. The company focuses on enhancing the application development process by providing tools that allow developer teams to create, run, and maintain tests efficiently. MoQuality's flagship product, Barista, offers a scriptless test automation experience, leveraging AI to generate user-centric test scenarios for mobile applications. This platform enables developers to conduct comprehensive end-to-end UI testing across various devices and operating systems, ensuring that applications are thoroughly vetted before reaching consumers. By streamlining the testing process, MoQuality aims to help developers deliver higher-quality apps and improve overall user experiences.

Accuitis, Inc. is a pre-clinical-stage biopharmaceutical company focused on acquiring, developing, and marketing innovative pharmaceuticals for niche, orphan, and underserved disease states. Founded in 2011, the company is headquartered in Alpharetta, Georgia. Accuitis specializes in the development of drug therapies for conditions such as rosacea and other topical skin diseases, as well as therapeutics for skin aging, acne, and dry eye. Through its targeted approach, Accuitis aims to address significant unmet medical needs in these areas.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

LymphaTech, Inc. is a healthcare technology company based in Atlanta, Georgia, focused on the treatment and prevention of lymphedema. Founded in 2014, the company has developed an innovative 3D body scanning technology that enables healthcare professionals to diagnose lymphedema more effectively and promptly. The device measures limb circumference to create accurate three-dimensional models, allowing for the monitoring of geometric changes over time. This technology can be utilized both in clinical settings and at home, facilitating early detection of symptoms and enabling timely intervention. By providing an easy-to-use mobile platform powered by proprietary algorithms, LymphaTech aims to enhance the quality of life for patients, particularly breast cancer survivors, while meeting critical needs in the healthcare community.

Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

Founded in 2007, Regeneus is a clinical-stage regenerative medicine company based in Sydney. It focuses on developing cell-based therapies targeting unmet medical needs, with an initial focus on osteoarthritis, neuropathic pain, and dermatology. Its lead platform technology, Progenza, is a cryopreserved multi-synergistic therapy for treating osteoarthritis and neuropathic pain.

MedShape is a privately held medical device company founded in 2005 based on a portfolio of proprietary surgical solutions that use its patented adaptive shape memory healing technologies to address the increasing demand for improved joint fusion, sports medicine, and musculoskeletal trauma products. MedShape® has enjoyed long-term support from Hills Capital Management, the Georgia Research Alliance (GRA), the National Science Foundation (NSF), the National Institutes of Health (NIH), and In-Q-Tel.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

Metaclipse Therapeutics develops next-generation cancer immunotherapies that use patient-derived tumor-membrane vesicles to activate the immune system against metastatic cancer. The autologous platform creates nanovesicles prepared from a patient's tumor tissue and augments them with proprietary immunostimulatory proteins to deliver tumor antigens and immune signals simultaneously. The approach is designed to generate robust, tumor-specific immunity that can destroy or suppress metastatic cancer cells originating from the patient's primary tumor. The company describes Membrex as a novel, personalized immunotherapy tailored to individual tumors, with aim of synergy with checkpoint inhibitors. Metaclipse operates in the preclinical/early development stage and seeks licensing partnerships with major pharmaceutical companies after establishing safety and efficacy. The technology targets multiple cancer types, including breast, prostate, renal cancer, melanoma, lymphoma, and ovarian cancer. Metaclipse is based in Atlanta, Georgia, focusing on therapies that activate the body's immune response to metastatic disease.

Metaclipse Therapeutics develops next-generation cancer immunotherapies that use patient-derived tumor-membrane vesicles to activate the immune system against metastatic cancer. The autologous platform creates nanovesicles prepared from a patient's tumor tissue and augments them with proprietary immunostimulatory proteins to deliver tumor antigens and immune signals simultaneously. The approach is designed to generate robust, tumor-specific immunity that can destroy or suppress metastatic cancer cells originating from the patient's primary tumor. The company describes Membrex as a novel, personalized immunotherapy tailored to individual tumors, with aim of synergy with checkpoint inhibitors. Metaclipse operates in the preclinical/early development stage and seeks licensing partnerships with major pharmaceutical companies after establishing safety and efficacy. The technology targets multiple cancer types, including breast, prostate, renal cancer, melanoma, lymphoma, and ovarian cancer. Metaclipse is based in Atlanta, Georgia, focusing on therapies that activate the body's immune response to metastatic disease.

Founded in 2007, Regeneus is a clinical-stage regenerative medicine company based in Sydney. It focuses on developing cell-based therapies targeting unmet medical needs, with an initial focus on osteoarthritis, neuropathic pain, and dermatology. Its lead platform technology, Progenza, is a cryopreserved multi-synergistic therapy for treating osteoarthritis and neuropathic pain.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

Metaclipse Therapeutics develops next-generation cancer immunotherapies that use patient-derived tumor-membrane vesicles to activate the immune system against metastatic cancer. The autologous platform creates nanovesicles prepared from a patient's tumor tissue and augments them with proprietary immunostimulatory proteins to deliver tumor antigens and immune signals simultaneously. The approach is designed to generate robust, tumor-specific immunity that can destroy or suppress metastatic cancer cells originating from the patient's primary tumor. The company describes Membrex as a novel, personalized immunotherapy tailored to individual tumors, with aim of synergy with checkpoint inhibitors. Metaclipse operates in the preclinical/early development stage and seeks licensing partnerships with major pharmaceutical companies after establishing safety and efficacy. The technology targets multiple cancer types, including breast, prostate, renal cancer, melanoma, lymphoma, and ovarian cancer. Metaclipse is based in Atlanta, Georgia, focusing on therapies that activate the body's immune response to metastatic disease.

Founded in 2007, Regeneus is a clinical-stage regenerative medicine company based in Sydney. It focuses on developing cell-based therapies targeting unmet medical needs, with an initial focus on osteoarthritis, neuropathic pain, and dermatology. Its lead platform technology, Progenza, is a cryopreserved multi-synergistic therapy for treating osteoarthritis and neuropathic pain.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

NeurOp is a biopharmaceutical company focused on developing medicines for central nervous system disorders. It develops disease-activated small molecules and therapies that target the GluN2B subunit of neuronal NMDA receptors, aiming to treat conditions such as ischemia, neuropathic pain, Parkinson’s disease, and Alzheimer's disease. Founded in 2002 and based in Atlanta, Georgia, the company concentrates on advancing treatments for CNS conditions that cause severe pain, neurodegeneration, and related symptoms.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

Whisper Communications is an Atlanta-based company that specializes in wireless networking services, leveraging innovative technologies to enhance data security. Utilizing patent-pending technology developed at the Georgia Institute of Technology, Whisper has created an encoding methodology that ensures data signals transmitted beyond a designated area, referred to as the "cone of silence," are rendered useless to eavesdroppers. The company's approach focuses on physical layer security, where the safety of data is intrinsically linked to its proximity to the data source. This enables IT companies to effectively monitor, track, and control devices located within a fixed area, thereby enhancing the overall security of wireless communications.

NeurOp is a biopharmaceutical company focused on developing medicines for central nervous system disorders. It develops disease-activated small molecules and therapies that target the GluN2B subunit of neuronal NMDA receptors, aiming to treat conditions such as ischemia, neuropathic pain, Parkinson’s disease, and Alzheimer's disease. Founded in 2002 and based in Atlanta, Georgia, the company concentrates on advancing treatments for CNS conditions that cause severe pain, neurodegeneration, and related symptoms.

Metaclipse Therapeutics develops next-generation cancer immunotherapies that use patient-derived tumor-membrane vesicles to activate the immune system against metastatic cancer. The autologous platform creates nanovesicles prepared from a patient's tumor tissue and augments them with proprietary immunostimulatory proteins to deliver tumor antigens and immune signals simultaneously. The approach is designed to generate robust, tumor-specific immunity that can destroy or suppress metastatic cancer cells originating from the patient's primary tumor. The company describes Membrex as a novel, personalized immunotherapy tailored to individual tumors, with aim of synergy with checkpoint inhibitors. Metaclipse operates in the preclinical/early development stage and seeks licensing partnerships with major pharmaceutical companies after establishing safety and efficacy. The technology targets multiple cancer types, including breast, prostate, renal cancer, melanoma, lymphoma, and ovarian cancer. Metaclipse is based in Atlanta, Georgia, focusing on therapies that activate the body's immune response to metastatic disease.

NeurOp is a biopharmaceutical company focused on developing medicines for central nervous system disorders. It develops disease-activated small molecules and therapies that target the GluN2B subunit of neuronal NMDA receptors, aiming to treat conditions such as ischemia, neuropathic pain, Parkinson’s disease, and Alzheimer's disease. Founded in 2002 and based in Atlanta, Georgia, the company concentrates on advancing treatments for CNS conditions that cause severe pain, neurodegeneration, and related symptoms.

NeurOp is a biopharmaceutical company focused on developing medicines for central nervous system disorders. It develops disease-activated small molecules and therapies that target the GluN2B subunit of neuronal NMDA receptors, aiming to treat conditions such as ischemia, neuropathic pain, Parkinson’s disease, and Alzheimer's disease. Founded in 2002 and based in Atlanta, Georgia, the company concentrates on advancing treatments for CNS conditions that cause severe pain, neurodegeneration, and related symptoms.

NeurOp is a biopharmaceutical company focused on developing medicines for central nervous system disorders. It develops disease-activated small molecules and therapies that target the GluN2B subunit of neuronal NMDA receptors, aiming to treat conditions such as ischemia, neuropathic pain, Parkinson’s disease, and Alzheimer's disease. Founded in 2002 and based in Atlanta, Georgia, the company concentrates on advancing treatments for CNS conditions that cause severe pain, neurodegeneration, and related symptoms.

NeurOp is a biopharmaceutical company focused on developing medicines for central nervous system disorders. It develops disease-activated small molecules and therapies that target the GluN2B subunit of neuronal NMDA receptors, aiming to treat conditions such as ischemia, neuropathic pain, Parkinson’s disease, and Alzheimer's disease. Founded in 2002 and based in Atlanta, Georgia, the company concentrates on advancing treatments for CNS conditions that cause severe pain, neurodegeneration, and related symptoms.